JP2023553534A5 - - Google Patents
Info
- Publication number
- JP2023553534A5 JP2023553534A5 JP2023560241A JP2023560241A JP2023553534A5 JP 2023553534 A5 JP2023553534 A5 JP 2023553534A5 JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023553534 A5 JP2023553534 A5 JP 2023553534A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- composition according
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124669P | 2020-12-11 | 2020-12-11 | |
| US63/124,669 | 2020-12-11 | ||
| US202163214736P | 2021-06-24 | 2021-06-24 | |
| US63/214,736 | 2021-06-24 | ||
| US202163277555P | 2021-11-09 | 2021-11-09 | |
| US63/277,555 | 2021-11-09 | ||
| US202163283035P | 2021-11-24 | 2021-11-24 | |
| US63/283,035 | 2021-11-24 | ||
| PCT/US2021/062927 WO2022125971A1 (en) | 2020-12-11 | 2021-12-10 | Combination therapies for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553534A JP2023553534A (ja) | 2023-12-21 |
| JP2023553534A5 true JP2023553534A5 (enExample) | 2024-12-17 |
Family
ID=81974015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560241A Pending JP2023553534A (ja) | 2020-12-11 | 2021-12-10 | 癌の処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250195533A1 (enExample) |
| EP (1) | EP4259639A4 (enExample) |
| JP (1) | JP2023553534A (enExample) |
| KR (1) | KR20230151981A (enExample) |
| AU (1) | AU2021397319A1 (enExample) |
| CA (1) | CA3201612A1 (enExample) |
| WO (1) | WO2022125971A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| EP4426303B1 (en) * | 2021-11-02 | 2025-10-08 | Semmelweis Egyetem | Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers |
| CN120112284A (zh) | 2022-08-19 | 2025-06-06 | 米拉蒂治疗股份有限公司 | 阿达格拉西布固体药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3013797B1 (en) * | 2013-06-28 | 2018-01-03 | BeiGene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| AU2018273356B2 (en) * | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CR20210175A (es) * | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| MX2021002804A (es) * | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| US20220152026A1 (en) * | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| JP2023553532A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
-
2021
- 2021-12-10 CA CA3201612A patent/CA3201612A1/en active Pending
- 2021-12-10 JP JP2023560241A patent/JP2023553534A/ja active Pending
- 2021-12-10 WO PCT/US2021/062927 patent/WO2022125971A1/en not_active Ceased
- 2021-12-10 KR KR1020237023425A patent/KR20230151981A/ko not_active Abandoned
- 2021-12-10 EP EP21904514.3A patent/EP4259639A4/en not_active Withdrawn
- 2021-12-10 US US18/256,091 patent/US20250195533A1/en active Pending
- 2021-12-10 AU AU2021397319A patent/AU2021397319A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023553534A5 (enExample) | ||
| US12552813B2 (en) | Heterocyclic substituted pyrimidopyran compound and use thereof | |
| JP2022121594A5 (enExample) | ||
| TWI331525B (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| WO2021110168A1 (zh) | 作为erk抑制剂的螺环类化合物及其应用 | |
| CA2472581A1 (en) | Tricyclic-bis-enone derivatives and methods of use thereof | |
| JP2006523216A5 (enExample) | ||
| JP2023506787A5 (enExample) | ||
| WO1992021345A1 (en) | Composition, method and kit for potentiating antitumor activity and for curing tumor | |
| JP7475055B2 (ja) | （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法 | |
| JP2023553533A5 (enExample) | ||
| JPS62502967A (ja) | 非潰瘍消化不良症の治療 | |
| US12064410B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory | |
| JP2024522817A5 (enExample) | ||
| JP2023553532A5 (enExample) | ||
| JP2021530554A5 (enExample) | ||
| JP2023503167A5 (enExample) | ||
| JP2024538730A5 (enExample) | ||
| JP2023517919A5 (enExample) | ||
| CN114209701A (zh) | 沃替西汀及其衍生物的抗肿瘤活性和应用 | |
| WO2024060911A1 (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
| KR20180059390A (ko) | 근육통과 관련된 상태의 치료를 위한 배합물 | |
| JP2022544559A5 (enExample) | ||
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| JP4608093B2 (ja) | 組合せ製剤としてのエンドセリン拮抗剤およびβ−受容体ブロッカー |